All In Biotech

Drug Trial Radar · NCT05732103

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Phase 1/2 Multicenter, Open-Label Study of CTX-712 in Patients With Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

225

Planned (sponsor's estimate)

Start

Apr 25, 2023

Primary completion

Jun 2028

Study completion Feb 2029

Sponsor

Lead sponsor
Chordia Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Theradex
First posted
Feb 16, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this phase 1/2 multicenter, open-label, single-arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS), or MDS/MPN (including CMML). The phase 1 part of the study consists of sequential standard 3 + 3 dose escalation, where patients will receive ascending doses of CTX-712 to determine the recommended phase 2 dose (RP2D) for further clinical development. This is followed by initial expansion cohorts in AML and/or HR-MDS where patients will be treated with CTX-712 at the RP2D to gain further confidence in the selected dose level. Additional expansion cohorts may be initiated if considered necessary. After RP2D is determined, Drug-Drug-Interaction cohorts will be started. The phase 2 part of the study will commence after the RP2D has been identified and confirmed and will evaluate therapeutic activity in R/R AML or R/R HR-MDS, in addition to confirmation of the safety profile.

Conditions

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes

Interventions

  • CTX-712Drug

    CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 once or twice weekly, depending on their dose level assignment, during each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Frequency of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) related to CTX-712.Time frame: Adverse events are collected from time of informed consent through 28 days after last dose of CTX-712.
  2. Phase 1: The maximum tolerated dose MTD.Time frame: Dose-limiting toxicities are collected during the first treatment cycle (28 days).
  3. Phase 2: Complete remission rate, defined as the proportion of patients who achieve complete remission.Time frame: Measured from date of first dose to 28 days after last dose of CTX-712.

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona · Recruiting

  • Mayo Clinic Florida

    Jacksonville, Florida · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • Mayo Clinic Comprehensive Cancer Center

    Rochester, Minnesota · Recruiting

  • The University of Rochester

    Rochester, New York · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Virginia

    Charlottesville, Virginia · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.